^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
valacyclovir
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Generic mfg.
Drug class:
DNA polymerase inhibitor
Related drugs:
2ms
Neonatal Phase 1 Valacyclovir Study (clinicaltrials.gov)
P1, N=17, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed
Trial completion
|
valacyclovir
3ms
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors (clinicaltrials.gov)
P1, N=11, Not yet recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Aug 2030 --> Nov 2030 | Initiation date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2030 --> Nov 2030
Trial completion date • Trial initiation date • Trial primary completion date
|
valacyclovir
4ms
Neonatal Phase 1 Valacyclovir Study (clinicaltrials.gov)
P1, N=17, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting
Enrollment closed
|
valacyclovir
4ms
Clinical Observation on the Treatment of herpes zoster with "specimen and acupoint combination" acupuncture (ChiCTR2500106201)
P=N/A, N=64, Not yet recruiting, Hubei Provincial Hospital of Traditional Chinese Medicine; Hubei Provincial Hospital of Traditional Chinese Medicine
New trial
|
valacyclovir
5ms
PrTK03: Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (clinicaltrials.gov)
P3, N=711, Active, not recruiting, Candel Therapeutics, Inc. | Trial completion date: Dec 2024 --> Dec 2030 | Trial primary completion date: Dec 2024 --> Aug 2024
Trial completion date • Trial primary completion date
|
ProstAtak (aglatimagene besadenovec) • valacyclovir
5ms
Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=12, Completed, Candel Therapeutics, Inc. | Active, not recruiting --> Completed
Trial completion
|
ProstAtak (aglatimagene besadenovec) • valacyclovir
5ms
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) (clinicaltrials.gov)
P2, N=187, Active, not recruiting, Candel Therapeutics, Inc.
Trial completion date
|
ProstAtak (aglatimagene besadenovec) • valacyclovir
6ms
Effect of Valaciclovir on Inter-Appointment Pain in Endodontic Treatment of Necrotic Teeth (clinicaltrials.gov)
P=N/A, N=38, Completed, Tehran University of Medical Sciences
New trial
|
valacyclovir
6ms
Valacyclovir in Pain Management of Acute Apical Abscesses (clinicaltrials.gov)
P2, N=60, Recruiting, University of California, San Francisco | N=250 --> 60 | Trial completion date: Nov 2024 --> Dec 2025 | Trial primary completion date: May 2024 --> Dec 2025
Enrollment change • Trial completion date • Trial primary completion date
|
valacyclovir
7ms
A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis (clinicaltrials.gov)
P1, N=16, Active, not recruiting, Shanghai BDgene Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Mar 2026
Enrollment closed • Trial completion date
|
prednisolone • valacyclovir
7ms
Neonatal Phase 1 Valacyclovir Study (clinicaltrials.gov)
P1, N=16, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Mar 2025 --> Aug 2025
Trial completion date • Trial primary completion date
|
valacyclovir
8ms
NCI-2022-07625: Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) (clinicaltrials.gov)
P2, N=60, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2025 --> Apr 2028 | Trial primary completion date: Apr 2025 --> Apr 2028
Trial completion date • Trial primary completion date
|
Venclexta (venetoclax) • Gazyva (obinutuzumab) • Jaypirca (pirtobrutinib) • valacyclovir
Share via
